NEW YORK (TheStreet) -- TheStreet's Jim Cramer talks about the breakout news of Regeneron (REGN) and its partner Sanofi (SNY) , which teamed up to create a cholesterol drug called alirocumab that would be used with the statin class of cholesterol drugs to decrease the hard-to-reduce cholesterol levels.
Cramer says this is great news for the approximately 12 million people who are allergic to the statin class. He thinks this is a multi-billion dollar drug for Regeneron and the company is finally breaking out. Cramer thinks this makes all sorts of sense because the drug cuts heart rate failure risk and stroke risk.
Cramer thinks Renegeron is a better way to play this news than Sanofi.
Must Read: Cramer: What's Working, What's NotSTOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more. REGN data by YCharts
EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he and Stephanie Link think could be potentially HUGE winners. Click here to see the holdings for FREE.
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts